Author: Zhou, Jingjing; Zhou, Jia; Sun, Zuoli; Feng, Lei; Zhu, Xuequan; Yang, Jian; Wang, Gang
Title: Development and Internal Validation of a Novel Model to Identify Inflammatory Biomarkers of a Response to Escitalopram in Patients With Major Depressive Disorder Cord-id: ak20jg32 Document date: 2021_5_20
ID: ak20jg32
Snippet: Objective: The aim of our study was to identify immune- and inflammation-related factors with clinical utility to predict the clinical efficacy of treatment for depression. Study Design: This was a follow-up study. Participants who met the entry criteria were administered with escitalopram (5–10 mg/day) as an initial treatment. Self-evaluation and observer valuations were arranged at the end of weeks 0, 4, 8, and 12, with blood samples collected at baseline and during weeks 2 and 12. Multivari
Document: Objective: The aim of our study was to identify immune- and inflammation-related factors with clinical utility to predict the clinical efficacy of treatment for depression. Study Design: This was a follow-up study. Participants who met the entry criteria were administered with escitalopram (5–10 mg/day) as an initial treatment. Self-evaluation and observer valuations were arranged at the end of weeks 0, 4, 8, and 12, with blood samples collected at baseline and during weeks 2 and 12. Multivariable logistic regression analysis was then carried out by incorporating three cytokines selected by the Least Absolute Shrinkage and Selection Operator (LASSO) regression model. Internal validation was estimated using the bootstrap method with 1,000 repetitions. Results: A total of 85 patients with Major Depressive Disorder (MDD), including 62 responders and 23 non-responders, were analyzed. Monocyte chemoattractant protein-1 (MCP-1), vascular cell adhesion molecule-1 (VCAM-1), and lipocalin-2 were selected by the LASSO regression model. The area under the curve (AUC) from the logistic model was 0.811 and was confirmed as 0.7887 following bootstrapping validation. Conclusions: We established and validated a good prediction model to facilitate the individualized prediction of escitalopram treatment for MDD and created a personalized approach to treatment for patients with depression.
Search related documents:
Co phrase search for related documents- absence presence and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- absence presence and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- absence presence and low detection: 1, 2, 3, 4
- absence presence and lymph node: 1, 2, 3, 4, 5
- absence presence and machine learning: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- absence presence and machine learning approach: 1
- absolute lasso selection shrinkage operator and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- absolute lasso selection shrinkage operator and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9
- absolute lasso selection shrinkage operator and lymph node: 1, 2, 3
- absolute lasso selection shrinkage operator and machine learning: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- accuracy confirm and low detection: 1
- accuracy confirm and lymph node: 1, 2
- accuracy confirm and machine learning: 1, 2
- acute phase and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute phase and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute phase and low detection: 1, 2
- acute phase and lymph node: 1, 2, 3, 4, 5
- acute phase and machine learning: 1, 2, 3, 4, 5, 6, 7, 8
- acute phase and machine learning approach: 1, 2
Co phrase search for related documents, hyperlinks ordered by date